Prospects of using Antagonist Histamine H2-Receptor (Cimetidinum) as Adjuvant for Melanoma Biotherapy Treatment

Details Prospects of using Antagonist Histamine H2-Receptor (Cimetidinum) as Adjuvant for Melanoma Biotherapy Treatment Prospects of using Antagonist Histamine H2-Receptor (Cimetidinum) as Adjuvant for Melanoma Biotherapy Treatment

2011-10-12

arxiv.org/abs/1110.2727v1

International Journal of Immunopathology, Allergology, Infectology 2010, #4: P. 42-51

Biology

Quantitative Biology

Tissues and Organs

14 pages, 5 figures; ISSN 0236-297X. International Journal of Immunopathology, Allergology, Infectology. 2010, #4: P. 42-51

Scientific paper

Improvement of anti-tumor biotherapy effectiveness by modification of immune response with histamine H2 receptor Cimetidinum (CM) was studied using the experimental murine model of B16 F10 melanoma in vivo. It is shown that skin melanoma biotherapy by antitumor whole-cell GM-CSF-producing vaccine with the addition of CM (in dose of 25 mg/kg, daily for 5 days) increases preventive effects of vaccination. 33 % of mice did not have tumor growth within 60 days of observation. Average life span of animals exceeded those of the control group up to 68 %. Using CM-combined bio-chemotherapy doesn't improve therapeutic effect, however in the case of a monotherapeutic approach tendency for increased average life-time and decreased metastatic processes in mice with the developed tumors was noticed. Aquired data provides expediency to study the further application of CM as adjuvant for skin melanoma vaccinotherapy, and also the necessity to verify the immune status of an organism against the complex bio-chemotherapy.

Affiliated with

Also associated with

No associations

Rating

Prospects of using Antagonist Histamine H2-Receptor (Cimetidinum) as Adjuvant for Melanoma Biotherapy Treatment does not yet have a rating. At this time, there are no reviews or comments for this scientific paper.

If you have personal experience with Prospects of using Antagonist Histamine H2-Receptor (Cimetidinum) as Adjuvant for Melanoma Biotherapy Treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prospects of using Antagonist Histamine H2-Receptor (Cimetidinum) as Adjuvant for Melanoma Biotherapy Treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFWR-SCP-O-634459